Multimodal imaging is a useful tool in diagnosing and managing age-related macular degeneration (AMD), according to Julie Rodman, OD, MS, FAAO.
Julie Rodman, OD, MS, FAAO, a professor in the Nova Southeastern University College of Optometry, discussed how multimodal imaging can be used in the management of age-related macular degeneration (AMD) ahead of her session on the topic to be held at the Southeastern Educational Congress of Optometry (SECO) 2025 meeting on Sunday, March 2.
This transcript has been lightly edited for clarity; captions were auto-generated.
Transcript
How can multimodal imaging be used to manage AMD?
Multimodal imaging essentially means either you're using OCT [optical coherence tomography], OCT angiography (OCT-A), fundus autofluorescence, fluorescent angiography—any test that's not just your basic, routine exam. We know, especially now with these new advances in geographic atrophy, that a lot of early disease findings are missed just based on clinical exam. OCT, OCT-A, [and] fundus autofluorescence do an amazing job, each of them in a different way, at identifying high-risk characteristics for both conversion to more advanced stages of disease and also just identification of the disease.
I would argue that any patient that has a wide-field imaging device, like an Optos, a Clarus, an Eidon, they probably have fundus autofluorescence on their camera. They should be getting not only color fundus photography, but also FAF [fundus autofluorescence] on every patient, because that provides that extra insight, or that extra sneak peek into what might be happening that we might not be seeing. It plays a huge role in providing ancillary information to a doctor. I hope that everybody that's practicing medical, optometry, retina, whatever it is, is using these devices in one way or another to supplement their exam.
How Pharmacy Deserts, Biosimilars, and Market Trends Are Shaping Managed Care
April 2nd 2025Rising biosimilar adoption, shifting market dynamics, and escalating supply chain vulnerabilities are driving change in managed care, creating both challenges and opportunities for stakeholders, as explored by speakers at the Academy of Managed Care Pharmacy’s annual meeting.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Areas of Unmet Need Continue to Burden Patients With gMG
April 2nd 2025Patient-reported outcomes measures in generalized myasthenia gravis (gMG) are more important than ever, for both those treating and being treated for the chronic autoimmune neuromuscular disorder, to have a more nuanced understanding of experiences and difficulties.
Read More
The IRA’s Unintended Consequences for Drug Pricing and Coverage
April 2nd 2025The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.
Read More